An Open Label, Phase I Study of BI 836880 Monotherapy and Combination Therapy of BI 836880 and BI 754091 in Japanese Patients With Advanced Solid Tumours
Latest Information Update: 25 Apr 2022
At a glance
- Drugs BI 836880 (Primary) ; Ezabenlimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim; Nippon Boehringer Ingelheim
Most Recent Events
- 21 Apr 2022 Status changed from active, no longer recruiting to completed.
- 13 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Apr 2022.
- 04 Jun 2021 Planned End Date changed from 19 Aug 2021 to 31 Dec 2021.